Publications by authors named "Rafael R Canevarolo"

Several therapeutic agents have been approved for treating multiple myeloma (MM), a cancer of bone marrow resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. Here, we present an integrated functional genomic analysis of tumor samples from MM patients that were assessed for their ex vivo drug sensitivity to 37 drugs, clinical variables, cytogenetics, mutational profiles, and transcriptomes.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied how combining ATR inhibitors (like BAY1895344) with MEK1/2 inhibitors (like cobimetinib) enhances the effectiveness of treating multiple myeloma (MM) by increasing cell death in MM cell lines.
  • The combination works by inactivating and downregulating STAT3, a protein linked to cell survival, leading to reduced levels of its targets, c-Myc and BCL-X, even in drug-resistant MM cells.
  • This combined treatment not only showed effectiveness against primary MM cells but also improved survival in MM models with low toxicity, highlighting its potential as a new therapeutic strategy for multiple myeloma patients.
View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma (MM) is a type of cancer that attacks the bones and is hard to cure because it can become resistant to treatments.
  • Researchers created a special computer model to study how MM cancer cells change and survive in the bone environment.
  • The model shows that protecting cells in the bone can help some cancer cells survive treatment, but targeting these protective effects could help make treatments work better and delay the disease from coming back.
View Article and Find Full Text PDF

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Although its prognosis continually improves with time, a significant proportion of patients still relapse from the disease because of the leukemia's resistance to therapy. Methotrexate (MTX), a folic-acid antagonist, is a chemotherapy agent commonly used against ALL and as an immune-system suppressant for rheumatoid arthritis that presents multiple and complex mechanisms of action and resistance.

View Article and Find Full Text PDF

Introduction: Methotrexate (MTX), a folic acid antagonist and nucleotide synthesis inhibitor, is a cornerstone drug used against acute lymphoblastic leukemia (ALL), but its mechanism of action and resistance continues to be unraveled even after decades of clinical use.

Methods: To better understand the mechanisms of this drug, we accessed the intracellular metabolic content of 13 ALL cell lines treated with MTX by 1H-NMR, and correlated metabolome data with cell proliferation and gene expression. Further, we validated these findings by inhibiting the cellular antioxidant system of the cells in vitro and in vivo in the presence of MTX.

View Article and Find Full Text PDF

Neoadjuvant chemotherapy (NACT) is offered to patients with operable or inoperable breast cancer (BC) to downstage the disease. Clinical responses to NACT may vary depending on a few known clinical and biological features, but the diversity of responses to NACT is not fully understood. In this study, 80 women had their metabolite profiles of pre-treatment sera analyzed for potential NACT response biomarker candidates in combination with immunohistochemical parameters using Nuclear Magnetic Resonance (NMR).

View Article and Find Full Text PDF
Article Synopsis
  • The text discusses a time-lapse microscopy technique used to study live cancer cells in a laboratory setting, helping to analyze their responses to various therapies in a way that could improve precision oncology.
  • A new software called CancerCellTracker was developed to track the behavior of these cells over time, detect cell deaths, and quantify cell viability using regular brightfield microscopy images, making the process more efficient and user-friendly.
  • The accuracy of CancerCellTracker was validated against established methods, and the software is publicly available for use and further research on GitHub.
View Article and Find Full Text PDF

The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due to HDAC inhibitor promiscuity with multiple HDACs. Therefore, more selective inhibition minimizing off-target toxicity may increase the clinical effectiveness of HDAC inhibitors. We demonstrated that plasma cell development and survival are dependent upon HDAC11, suggesting this enzyme is a promising therapeutic target in MM.

View Article and Find Full Text PDF

Interactions between the inhibitor of apoptosis protein antagonist LCL161 and the histone deacetylase inhibitor panobinostat (LBH589) were examined in human multiple myeloma (MM) cells. LCL161 and panobinostat interacted synergistically to induce apoptosis in diverse MM cell lines, including those resistant to bortezomib (PS-R). Similar interactions were observed with other histone deacetylase inhibitors (MS-275) or inhibitors of apoptosis protein antagonists (birinapant).

View Article and Find Full Text PDF

This study aimed to evaluate the impact of aerobic training (AT) on autonomic, cardiometabolic, ubiquitin-proteasome activity, and inflammatory changes evoked by myocardial infarction (MI) in ovariectomized rats. Female Wistar rats were ovariectomized and divided into four groups: sedentary + sham (SS), sedentary + MI (SI), AT + sham surgery (TS), AT + MI (TI). AT was performed on a treadmill for 8 weeks before MI.

View Article and Find Full Text PDF
Article Synopsis
  • Multiagent therapies are crucial in treating multiple myeloma (MM) as they can help delay or bypass drug resistance, necessitating advanced screening methods for personalized treatment.
  • A new pharmacodynamic model was developed to analyze two-drug combinations, showing strong predictive capabilities when compared to actual patient responses and reconciling existing synergy models by incorporating the element of time.
  • While 21.43% of tested drug combinations showed synergistic effects in lab settings, only 8.69% were predicted to be clinically synergistic, highlighting the importance of pharmacokinetics and dosing on real-world effectiveness.
View Article and Find Full Text PDF

Tubulin is one of the best validated anti-cancer targets, but most anti-tubulin agents have unfavorable therapeutic indexes. Here, we characterized the tubulin-binding activity, the mechanism of action, and the in vivo anti-leukemia efficacy of three 3,4,5-trimethoxy-N-acylhydrazones. We show that all compounds target the colchicine-binding site of tubulin and that none is a substrate of ABC transporters.

View Article and Find Full Text PDF

Titanium dioxide (TiO2) has attracted attention as a photosensitizer in the field of photodynamic therapy (PDT) due to its low toxicity and high photostability. In the present work, nitrogen-doped TiO2 (N-TiO2) nanoparticles had their photokilling efficiency evaluated on a murine melanoma cell line (B16-F10) and fibroblasts (NIH 3T3). The N-TiO2 nanoparticles were prepared by a modified hydrogen peroxide sol-gel process using triethylamine as nitrogen precursor.

View Article and Find Full Text PDF

The present study aimed to compare the early metabolic response between high-load resistance exercise (HL-RE) and low-load resistance exercise with blood flow restriction (LL-BFR). Nine young, well-trained men participated in a randomized crossover design in which each subject completed LL-BFR, HL-RE, or condition control (no exercise) with a 1-week interval between them. Blood samples were taken immediately before and 5 min after the exercise sessions.

View Article and Find Full Text PDF

This study analysed the time course of the global metabolic acute response after resistance exercise (RE), with the use of proton nuclear magnetic resonance (H NMR) spectroscopy. Ten young healthy males performed 4 sets of 10 repetitions at 70% of one-repetition maximum in the leg press and knee extension exercises and had the serum metabolome assessed at 5, 15, 30 and 60 min post-RE. Measurements were also performed 1 h earlier and immediately before the exercises, as an attempt to characterise each participant's serum metabolome at rest.

View Article and Find Full Text PDF

Targeted proteomics has flourished as the method of choice for prospecting for and validating potential candidate biomarkers in many diseases. However, challenges still remain due to the lack of standardized routines that can prioritize a limited number of proteins to be further validated in human samples. To help researchers identify candidate biomarkers that best characterize their samples under study, a well-designed integrative analysis pipeline, comprising MS-based discovery, feature selection methods, clustering techniques, bioinformatic analyses and targeted approaches was performed using discovery-based proteomic data from the secretomes of three classes of human cell lines (carcinoma, melanoma and non-cancerous).

View Article and Find Full Text PDF

Tubulin-interacting agents, like vinca alkaloid and taxanes, play a fundamental role in cancer chemotherapy, making cellular microtubules (MT), one of the few validated anticancer targets. Cancer resistance to classical MT inhibitors has motivated the development of novel molecules with increased efficacy and lower toxicity. Aiming at designing structurally-simple inhibitors of MT assembly, we synthesized a series of thirty-one 3,4,5-trimethoxy-hydrazones and twenty-five derivatives or analogs.

View Article and Find Full Text PDF

Xanthomonas is a genus of phytopathogenic bacteria, which produces a slimy, polysaccharide matrix known as xanthan gum, which involves, protects and helps the bacteria during host colonization. Although broadly used as a stabilizer and thickener in the cosmetic and food industries, xanthan gum can be a troubling artifact in molecular investigations due to its rheological properties. In particular, a cross-reaction between reference compounds and the xanthan gum could compromise metabolic quantification by NMR spectroscopy.

View Article and Find Full Text PDF

Based on classical colchicine site ligands and a computational model of the colchicine binding site on beta tubulin, two classes of chalcone derivatives were designed, synthesized and evaluated for inhibition of tubulin assembly and toxicity in human cancer cell lines. Docking studies suggested that the chalcone scaffold could fit the colchicine site on tubulin in an orientation similar to that of the natural product. In particular, a 3,4,5-trimethoxyphenyl ring adjacent to the carbonyl group appeared to benefit the ligand-tubulin interaction, occupying the same subcavity as the corresponding moiety in colchicine.

View Article and Find Full Text PDF